Cargando…
Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
Neuroblastoma is the most common solid tumor in children with an estimated 5-year progression free survival of 20–40% in stage 4 disease. Neuroblastoma actively avoids recognition by natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Although immunotherapy has gained traction for neurobla...
Autores principales: | Spel, Lotte, Boelens, Jaap-Jan, van der Steen, Dirk M., Blokland, Nina J.G., van Noesel, Max M., Molenaar, Jan J., Heemskerk, Mirjam H.M., Boes, Marianne, Nierkens, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742140/ https://www.ncbi.nlm.nih.gov/pubmed/26452036 |
Ejemplares similares
-
Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation
por: Spel, Lotte, et al.
Publicado: (2013) -
Development of a unique anti-AML immune therapy consisting of cord blood HSCT and cord blood stem cell-derived dendritic cell (CB-DC) vaccination
por: de Haar, Colin, et al.
Publicado: (2013) -
PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
por: Luk, Sietse J, et al.
Publicado: (2018) -
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
por: van Amerongen, Rosa A., et al.
Publicado: (2023) -
Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies
por: Cornel, Annelisa M., et al.
Publicado: (2018)